Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

862 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.
Miles D, Gligorov J, André F, Cameron D, Schneeweiss A, Barrios C, Xu B, Wardley A, Kaen D, Andrade L, Semiglazov V, Reinisch M, Patel S, Patre M, Morales L, Patel SL, Kaul M, Barata T, O'Shaughnessy J; IMpassion131 investigators. Miles D, et al. Ann Oncol. 2021 Aug;32(8):994-1004. doi: 10.1016/j.annonc.2021.05.801. Epub 2021 Jul 1. Ann Oncol. 2021. PMID: 34219000 Free article. Clinical Trial.
Impact of interventions on mpox transmission during the 2022 outbreak in Canada: a mathematical modeling study of three different cities.
Xiu F, Doyle C, Anato JLF, Knight J, Wang L, Cox J, Grace D, Hart TA, Zhang T, Skakoon-Sparling S, Dvorakova M, Shahin R, Sachdeva H, Lachowsky N, Sbihi H, Tan DHS, Irvine MA, Mishra S, Maheu-Giroux M. Xiu F, et al. Among authors: doyle c. Int J Infect Dis. 2025 Jan 21:107792. doi: 10.1016/j.ijid.2025.107792. Online ahead of print. Int J Infect Dis. 2025. PMID: 39848438
A Canadian real-world, multi-center, prospective, observational study assessing the treatment duration, the treatment sequence, and the overall survival for patients treated with endocrine therapy ± targeted therapy in HR + HER2-negative advanced breast cancer.
Doyle C, Lohmann AE, Iqbal N, Henning JW, Kulkarni S, Califaretti N, Hilton J, Ferrario C, Bouganim N, Mates M, Guillemette S, Leite R, Caron MA, Thireau F, Machado A, Chia S. Doyle C, et al. Breast Cancer Res Treat. 2025 Jan 23. doi: 10.1007/s10549-024-07580-8. Online ahead of print. Breast Cancer Res Treat. 2025. PMID: 39847203
862 results